Boston Therapeutics Inc. (BTHE)
|Net Income (ttm)||-2.71M|
|Trading Day||March 5|
|Day's Range||0.0298 - 0.0387|
|52-Week Range||0.0055 - 0.06|
There are no news available yet.
Boston Therapeutics, a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical tr... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, BTHE's revenue was $16,329, a decrease of -48.53% compared to the previous year's $31,723. Losses were -$3.69 million, 2.58% more than in 2018.